Almost 5 BILLION individuals worldwide will have some form of myopia by 2050

7-Methylxanthine (7-MX) presents an alternative to expensive and inaccessible surgical treatments

We optimized the catalytic efficiency of
caffeine-degrading enzymes to efficiently generate 7-MX

We designed a biochemical reactor, carrying alginate beads with encapsulated modified enzymes

We used increasingly sophisticated in silico models to influence methodologies for epPCR and reactor design

Over the next 10 years, ENERGEM will serve as a case study as
we diversify our product portfolio and expand our target markets

Through outreach events and an interactive game, ENERGEM is a tool to educate the next generation of scientists